Second Quarter 2023 and Recent Selected Highlights:
- Record revenues of $33.5 million, an increase of 44% over $23.3
million in the prior-year quarter and an increase of 28% over $26.1
million in the sequential quarter.
- GAAP net loss of ($4.2) million.
- Record adjusted EBITDA of $11.0 million, an increase of 144%
over $4.5 million in the prior‑year quarter and an increase of 108%
over $5.3 million in the sequential quarter.
- Completed public offering of common stock for aggregate gross
proceeds of $69 million.
- Expanded Oaktree Loan from $100 million to $112.50
million.
- Acquired certain commercial rights to FLAREX®, NATACYN®,
TOBRADEX® ST, VERKAZIA®, ZERVIATE®, and Non-Prescription Brands
FRESHKOTE® and Cationorm® PLUS.
- Acquired North American commercial rights to VEVYE®, a novel
FDA-approved drug labeled to treat both the signs and symptoms of
dry eye disease.
- Completed transfer of New Drug Application for VIGAMOX®.
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical
company, today announced results for the second quarter and six
months ended June 30, 2023. The Company also posted its second
quarter Letter to Stockholders and corporate presentation to the
“Investors” section of its website, harrow.com.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230809749685/en/
“Our team has made great progress positioning Harrow as a
top-tier U.S.-focused ophthalmic pharmaceutical company,” said Mark
L. Baum, CEO of Harrow. “Since January of 2023, through a series of
transactions, we have not only improved Harrow’s balance sheet, but
we’ve dramatically improved Harrow’s product portfolio, which is
now one of the most comprehensive ophthalmic pharmaceutical
offerings in the U.S. market. With what we now have in our “bag”
and continued execution and operational performance by the Harrow
team, we believe we are on our way to achieving the highest
financial goals for Harrow’s stockholders.”
Second quarter 2023 figures of merit:
For the Three Months Ended
June 30,
For the Six Months Ended June
30,
2023
2022
2023
2022
Net revenues
$
33,470,000
$
23,323,000
$
59,573,000
$
45,443,000
Gross margin
70
%
72
%
69
%
72
%
Core gross margin(1)
78
%
73
%
77
%
74
%
Net loss
(4,229,000
)
(6,239,000
)
(10,872,000
)
(8,677,000
)
Core net (loss) income(1)
(494,000
)
254,000
(1,536,000
)
967,000
Adjusted EBITDA(1)
11,005,000
4,505,000
16,347,000
9,445,000
Basic net loss per share
(0.14
)
(0.23
)
(0.36
)
(0.32
)
Diluted net loss per share
(0.14
)
(0.23
)
(0.36
)
(0.32
)
Core basic net (loss) income per
share(1)
(0.02
)
0.01
(0.05
)
0.04
Core diluted net (loss) income per
share(1)
(0.02
)
0.01
(0.05
)
0.03
(1)
Core gross margin, core net (loss) income,
core basic and diluted net (loss) income per share (collectively,
“Core Results”), and Adjusted EBITDA are non GAAP measures. For
additional information, including a reconciliation of such Core
Results and Adjusted EBITDA to the most directly comparable
measures presented in accordance with GAAP, see the explanation of
non-GAAP measures and reconciliation tables in the financial tables
section.
Conference Call and Webcast
The Company’s management team will host a conference call and
live webcast today at 4:45 p.m. Eastern Time to discuss the second
quarter 2023 results and provide a business update. To participate
in the call, see details below:
Conference Call Details:
Date:
Wednesday, August 9, 2023
Time:
4:45 p.m. Eastern time
Participant Dial-in:
1-833-953-2434 (U.S.) 1-412-317-5763
(International)
Replay Dial-in (Passcode
3750229):
(telephonic replay through August 16,
2023)
1-877-344-7529 (U.S.) 1-412-317-0088
(International)
Webcast: (online replay through August
9, 2024)
harrow.com
About Harrow
Harrow Health, Inc. (Nasdaq: HROW) is a leading eyecare
pharmaceutical company engaged in the discovery, development, and
commercialization of innovative ophthalmic pharmaceutical products
for the U.S. market. Harrow helps U.S. eyecare professionals
preserve the gift of sight by making its comprehensive portfolio of
prescription and non-prescription pharmaceutical products
accessible and affordable to millions of Americans each year. For
more information about Harrow, please visit harrow.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such “forward-looking statements.”
Forward-looking statements are based on management's current
expectations and are subject to risks and uncertainties which may
cause results to differ materially and adversely from the
statements contained herein. Some of the potential risks and
uncertainties that could cause actual results to differ from those
predicted include, among others, risks related to: liquidity or
results of operations; our ability to successfully implement our
business plan, develop and commercialize our products, product
candidates and proprietary formulations in a timely manner or at
all, identify and acquire additional products, manage our pharmacy
operations, service our debt, obtain financing necessary to operate
our business, recruit and retain qualified personnel, manage any
growth we may experience and successfully realize the benefits of
our previous acquisitions and any other acquisitions and
collaborative arrangements we may pursue; competition from
pharmaceutical companies, outsourcing facilities and pharmacies;
general economic and business conditions, including inflation and
supply chain challenges; regulatory and legal risks and
uncertainties related to our pharmacy operations and the pharmacy
and pharmaceutical business in general; physician interest in and
market acceptance of our current and any future formulations and
compounding pharmacies generally. These and additional risks and
uncertainties are more fully described in Harrow’s filings with the
Securities and Exchange Commission, including its Annual Report on
Form 10-K and its Quarterly Reports on Form 10-Q. Such documents
may be read free of charge on the SEC's web site at sec.gov. Undue
reliance should not be placed on forward-looking statements, which
speak only as of the date they are made. Except as required by law,
Harrow undertakes no obligation to update any forward-looking
statements to reflect new information, events, or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
HARROW HEALTH, INC.
CONDENSED CONSOLIDATED BALANCE
SHEETS
June 30, 2023
December 31, 2022
(unaudited)
ASSETS
Cash and cash equivalents
$
22,754,000
$
96,270,000
All other current assets
37,542,000
21,990,000
Total current assets
60,296,000
118,260,000
All other assets
163,693,000
39,118,000
TOTAL ASSETS
$
223,989,000
$
157,378,000
LIABILITIES AND STOCKHOLDERS'
EQUITY
Current liabilities
$
23,011,000
$
18,632,000
Loans payable, net of current portion and
unamortized debt discount
169,712,000
104,174,000
All other liabilities
9,214,000
7,332,000
TOTAL LIABILITIES
201,937,000
130,138,000
TOTAL STOCKHOLDERS' EQUITY
22,052,000
27,240,000
TOTAL LIABILITIES AND STOCKHOLDERS'
EQUITY
$
223,989,000
$
157,378,000
HARROW HEALTH, INC.
UNAUDITED CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS
For the Three Months Ended
June 30,
For the Six Months Ended June
30,
2023
2022
2023
2022
Total revenues
$
33,470,000
$
23,323,000
$
59,573,000
$
45,443,000
Cost of sales
10,000,000
6,534,000
18,271,000
12,497,000
Gross profit
23,470,000
16,789,000
41,302,000
32,946,000
Selling, general and administrative
19,957,000
14,185,000
35,845,000
27,583,000
Research and development
1,161,000
914,000
1,895,000
1,572,000
Total operating expenses
21,118,000
15,099,000
37,740,000
29,155,000
Income from operations
2,352,000
1,690,000
3,562,000
3,791,000
Total other expense, net
6,596,000
7,889,000
14,737,000
12,428,000
Income tax benefit (expense)
15,000
(40,000
)
303,000
(40,000
)
Net loss attributable to Harrow
Health, Inc.
$
(4,229,000
)
$
(6,239,000
)
$
(10,872,000
)
$
(8,677,000
)
Net loss per share of common stock,
basic and diluted
$
(0.14
)
$
(0.23
)
$
(0.36
)
$
(0.32
)
HARROW HEALTH, INC.
UNAUDITED CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Six Months
Ended
June 30,
2023
2022
Net cash (used in) provided by:
Operating activities
$
(3,648,000
)
$
5,827,000
Investing activities
(132,219,000
)
(669,000
)
Financing activities
62,351,000
(887,000
)
Net change in cash and cash
equivalents
(73,516,000
)
4,271,000
Cash and cash equivalents at beginning of
the period
96,270,000
42,167,000
Cash and cash equivalents at end of the
period
$
22,754,000
$
46,438,000
Non-GAAP Financial Measures
In addition to the Company’s results of operations determined in
accordance with U.S. generally accepted accounting principles
(GAAP), which are presented and discussed above, management also
utilizes Adjusted EBITDA and Core Results, unaudited financial
measures that are not calculated in accordance with GAAP, to
evaluate the Company’s financial results and performance and to
plan and forecast future periods. Adjusted EBITDA and Core Results
are considered “non‑GAAP” financial measures within the meaning of
Regulation G promulgated by the SEC. Management believes that these
non-GAAP financial measures reflect an additional way of viewing
aspects of the Company’s operations that, when viewed with GAAP
results, provide a more complete understanding of the Company’s
results of operations and the factors and trends affecting its
business. Management believes Adjusted EBITDA and Core Results
provide meaningful supplemental information regarding the Company’s
performance because (i) they allow for greater transparency with
respect to key metrics used by management in its financial and
operational decision-making; (ii) they exclude the impact of
non-cash or, when specified, non-recurring items that are not
directly attributable to the Company’s core operating performance
and that may obscure trends in the Company’s core operating
performance; and (iii) they are used by institutional investors and
the analyst community to help analyze the Company’s results.
However, Adjusted EBITDA, Core Results, and any other non-GAAP
financial measures should be considered as a supplement to, and not
as a substitute for, or superior to, the corresponding measures
calculated in accordance with GAAP. Further, non‑GAAP financial
measures used by the Company and the way they are calculated may
differ from the non-GAAP financial measures or the calculations of
the same non‑GAAP financial measures used by other companies,
including the Company’s competitors.
Adjusted EBITDA
The Company defines Adjusted EBITDA as net (loss) income,
excluding the effects of stock‑based compensation and expenses,
interest, taxes, depreciation, amortization, investment (loss)
income, net, and, if any and when specified, other non-recurring
income or expense items. Management believes that the most directly
comparable GAAP financial measure to Adjusted EBITDA is net (loss)
income. Adjusted EBITDA has limitations and should not be
considered as an alternative to gross profit or net (loss) income
as a measure of operating performance or to net cash provided by
(used in) operating, investing, or financing activities as a
measure of ability to meet cash needs.
The following is a reconciliation of Adjusted EBITDA, a non-GAAP
measure, to the most comparable GAAP measure, net loss, for the
three months and six months ended June 30, 2023, and for the same
periods in 2022:
HARROW HEALTH, INC.
RECONCILIATION OF NET LOSS TO
ADJUSTED EBITDA
For the Three Months Ended
June 30,
For the Six Months Ended June
30,
2023
2022
2023
2022
GAAP net loss
$
(4,229,000
)
$
(6,239,000
)
$
(10,872,000
)
$
(8,677,000
)
Stock-based compensation and expenses
5,412,000
1,993,000
7,045,000
4,009,000
Interest expense, net
5,704,000
1,794,000
10,451,000
3,586,000
Income tax expense (benefit)
(15,000
)
40,000
(303,000
)
40,000
Depreciation
398,000
424,000
690,000
843,000
Amortization of intangible assets
2,843,000
398,000
5,050,000
802,000
Investment loss (income), net
714,000
6,095,000
(1,328,000
)
8,842,000
Other expense, net
178,000
-
5,614,000
(1)
-
Adjusted EBITDA
$
11,005,000
$
4,505,000
$
16,347,000
$
9,445,000
(1)
Includes $5,465,000 for the loss on
extinguishment of debt.
Core Results
Harrow Core Results, including core gross margin, core net
income (loss), core operating income, core basic and diluted income
(loss) per share, and core operating margin, exclude all
amortization and impairment charges of intangible assets, excluding
software development costs, net gains and losses on investments and
equity securities, including equity method gains and losses and
equity valued at fair value through profit and loss (“FVPL”),
preferred stock dividends, and gains/losses on forgiveness of debt.
In other periods, Core Results may also exclude fair value
adjustments of financial assets in the form of options to acquire a
company carried at FVPL, obligations related to product recalls,
certain acquisition‑related items, restructuring charges/releases
and associated items, related legal items, gains/losses on early
extinguishment of debt or debt modifications, impairments of
property, plant and equipment and software, as well as income and
expense items that management deems exceptional and that are or are
expected to accumulate within the year to be over a $100,000
threshold.
The following is a reconciliation of Core Results, non-GAAP
measures, to the most comparable GAAP measures for the three and
six months ended June 30, 2023, and for the same periods in
2022:
For the Three Months Ended
June 30, 2023
GAAP
Results
Amortization of Certain
Intangible Assets
Investment
Gains
Other
Items
Core
Results
Gross profit
$
23,470,000
$
2,649,000
$
-
$
-
$
26,119,000
Gross margin
70
%
78
%
Operating income
2,352,000
2,843,000
-
-
5,195,000
(Loss) income before taxes
(4,244,000
)
2,843,000
714,000
178,000
(509,000
)
Tax benefit
15,000
-
-
-
15,000
Net (loss) income
(4,229,000
)
2,843,000
714,000
178,000
(494,000
)
Basic and diluted loss per share
($)(1)
(0.14
)
(0.02
)
Weighted average number of shares of
common stock outstanding, basic and diluted
30,458,677
30,458,677
For the Six Months Ended June
30, 2023
GAAP
Results
Amortization of Certain
Intangible Assets
Investment
Losses
Other
Items
Core
Results
Gross profit
$
41,302,000
$
4,694,000
$
-
$
-
$
45,996,000
Gross margin
69
%
77
%
Operating income
3,562,000
5,050,000
-
-
8,612,000
(Loss) income before taxes
(11,175,000
)
5,050,000
(1,328,000
)
5,614,000
(1,839,000
)
Tax benefit
303,000
-
-
-
303,000
Net (loss) income
(10,872,000
)
5,050,000
(1,328,000
)
5,614,000
(1,536,000
)
Basic and diluted loss per share
($)(1)
(0.36
)
(0.05
)
Weighted average number of shares of
common stock outstanding, basic and diluted
30,379,354
30,379,354
For the Three Months Ended
June 30, 2022
GAAP
Results
Amortization of Certain
Intangible
Assets
Investment
Gains
Core
Results
Gross profit
$
16,789,000
$
341,000
$
-
$
17,130,000
Gross margin
72
%
73
%
Operating income
1,690,000
398,000
-
2,088,000
(Loss) income before taxes
(6,199,000
)
398,000
6,095,000
294,000
Taxes
(40,000
)
-
-
(40,000
)
Net (loss) income
(6,239,000
)
398,000
6,095,000
254,000
Basic (loss) earnings per share ($)(1)
(0.23
)
0.01
Diluted (loss) earnings per share
($)(1)
(0.23
)
0.01
Weighted average number of shares of
common stock outstanding:
Basic
27,303,458
27,303,458
Diluted
27,303,458
28,234,177
For the Six Months Ended June
30, 2022
GAAP
Results
Amortization of Certain
Intangible
Assets
Investment
Gains
Core
Results
Gross profit
$
32,946,000
$
682,000
$
-
$
33,628,000
Gross margin
72
%
74
%
Operating income
3,791,000
802,000
-
4,593,000
(Loss) Income before taxes
(8,637,000
)
802,000
8,842,000
1,007,000
Taxes
(40,000
)
-
-
(40,000
)
Net (loss) income
(8,677,000
)
802,000
8,842,000
967,000
Basic (loss) earnings per share ($)(1)
(0.32
)
0.04
Diluted (loss) earnings per share
($)(1)
(0.32
)
0.03
Weighted average number of shares of
common stock outstanding:
Basic
27,265,350
27,265,350
Diluted
27,265,350
28,270,639
(1)
Core basic and diluted (loss) earnings per
share is calculated using the weighted-average number of shares of
common stock outstanding during the period. Core basic and diluted
(loss) earnings per share also contemplates dilutive shares
associated with equity-based awards as described in Note 2 and
elsewhere in the Condensed Consolidated Financial Statements
included in the Company’s Quarterly Report on Form 10-Q for the
quarter ended June 30, 2023.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230809749685/en/
Jamie Webb, Director of Communications and Investor Relations
jwebb@harrowinc.com 615-733-4737
Harrow (NASDAQ:HROW)
Historical Stock Chart
From Dec 2024 to Jan 2025
Harrow (NASDAQ:HROW)
Historical Stock Chart
From Jan 2024 to Jan 2025
